WallStreetZenWallStreetZen

NASDAQ: JUNS
Jupiter Neurosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their JUNS stock forecasts and price targets.

Forecast return on equity

Is JUNS forecast to generate an efficient return?

Company
-15,900.99%
Industry
89.85%
Market
357.07%
JUNS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is JUNS forecast to generate an efficient return on assets?

Company
-354.38%
Industry
27.44%
JUNS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

JUNS earnings per share forecast

What is JUNS's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.06
Avg 2 year Forecast
-$0.27

JUNS revenue forecast

What is JUNS's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$12.4M
Avg 2 year Forecast
$7.5M

JUNS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
JUNS$0.59N/AN/A
LIXT$3.56N/AN/A
CASI$0.99$4.00+305.68%Buy
IOBT$0.28$2.25+709.35%Buy
LEXX$0.79$1.50+89.39%Buy
View Top Biotech Stocks

Jupiter Neurosciences Stock Forecast FAQ

What is JUNS's earnings growth forecast for 2026-2027?

(NASDAQ: JUNS) Jupiter Neurosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 200.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,218.89%.

Jupiter Neurosciences's earnings in 2026 is -$7,597,493.On average, 3 Wall Street analysts forecast JUNS's earnings for 2026 to be $2,106,893, with the lowest JUNS earnings forecast at $2,024,270, and the highest JUNS earnings forecast at $2,168,860.

In 2027, JUNS is forecast to generate -$9,129,869 in earnings, with the lowest earnings forecast at -$8,771,835 and the highest earnings forecast at -$9,398,395.

If you're new to stock investing, here's how to buy Jupiter Neurosciences stock.

What is JUNS's revenue growth forecast for 2026-2027?

(NASDAQ: JUNS) Jupiter Neurosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 11,996.93%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,540.38%.

Jupiter Neurosciences's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast JUNS's revenue for 2026 to be $426,026,143, with the lowest JUNS revenue forecast at $409,294,935, and the highest JUNS revenue forecast at $438,557,336.

In 2027, JUNS is forecast to generate $258,369,794 in revenue, with the lowest revenue forecast at $248,248,446 and the highest revenue forecast at $265,978,019.

What is JUNS's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: JUNS) forecast ROA is -354.38%, which is lower than the forecast US Biotechnology industry average of 27.44%.

What is JUNS's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: JUNS) Jupiter Neurosciences's current Earnings Per Share (EPS) is -$0.24. On average, analysts forecast that JUNS's EPS will be $0.06 for 2026, with the lowest EPS forecast at $0.06, and the highest EPS forecast at $0.06. In 2027, JUNS's EPS is forecast to hit -$0.27 (min: -$0.25, max: -$0.27).

What is JUNS's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: JUNS) forecast ROE is -15,900.99%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.